Gemeinschaftspraxis Dr. med. Johannes Mohm, Dr. med. Virag Siklaky, Stefanie Mann

At Gemeinschaftspraxis Dr. med. Johannes Mohm, Dr. med. Virag Siklaky, Stefanie Mann in Dresden, clinical research in Oncology strongly focuses on hemic and lymphatic diseases, especially lymphomas and chronic lymphocytic leukemia. These studies are designed to improve treatment effectiveness, refine disease control, and identify better long-term outcomes for patients with aggressive or high-risk blood cancers.

• Advanced stage Hodgkin lymphoma research aimed at improving disease control and survival
• Mantle cell lymphoma studies evaluating new treatment strategies before and after transplant
• Diffuse large B-cell lymphoma and related subtypes research testing more effective therapy combinations for older or high-risk patients
• Chronic lymphocytic leukemia trials focused on better progression-free survival in patients with high-risk features

The site’s work in hematologic oncology highlights efforts to compare established treatments with newer combinations, with the goal of improving outcomes while maintaining tolerability.

Another major area of activity is breast cancer, with trials covering both early-stage and metastatic HR-positive, HER2-negative disease. The research is centered on testing whether new treatment approaches can strengthen disease-free survival, support longer disease stabilization, and guide smarter use of endocrine-based therapy.

• HR+/HER2- early breast cancer studies assessing whether adding targeted treatment can improve invasive disease-free survival
• Metastatic HR positive, HER2 negative breast cancer research exploring whether treatment can be safely simplified after durable control
• Trials focused on optimizing endocrine therapy and targeted combinations for patients with intermediate to high risk disease

This research reflects a clear interest in improving long-term outcomes in breast oncology while balancing efficacy with quality of life.

The site also contributes to gastrointestinal cancer research, including studies in locally advanced rectal cancer. These trials are designed to evaluate how treatment sequencing can improve disease-free survival and support more personalized care for patients with surgically treated colorectal cancer.

• Locally advanced rectal cancer research examining whether treatment planning can better reduce recurrence and progression
• Studies aimed at improving disease-free survival through more tailored use of systemic therapy

This work adds an important solid-tumor dimension to the clinical trial portfolio at the Dresden site.

Across its oncology trials, the site is involved in research that compares standard care with newer targeted approaches, including BTK inhibitors, CDK4/6 inhibitors, and other modern cancer therapies. The overall purpose is to improve survival, reduce toxicity where possible, and identify treatment strategies that are more effective for specific disease subgroups.

• Testing whether newer combinations can improve outcomes in lymphoma and CLL
• Evaluating whether targeted treatment can enhance breast cancer control
• Studying approaches that may reduce treatment burden while preserving effectiveness

With 7 trials and 2 investigators, the site shows a focused but diverse commitment to advancing oncology clinical research in both blood cancers and solid tumors.